Journal of Research in Ayurvedic Sciences

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2019 ) > List of Articles

ORIGINAL RESEARCH ARTICLE

Clinical Efficacy and Safety of Brihat Gangadhara Churna in the Management of Irritable Bowel Syndrome: A Prospective Open-label Study

Debajyoti Das, Bhagwan Sahai Sharma, Achintya Mitra, Bidhan Mahajon

Keywords : Grahani, Irritable bowel syndrome, Irritable bowel syndrome severity score,Brihat Gangadhara Churna

Citation Information : Das D, Sharma BS, Mitra A, Mahajon B. Clinical Efficacy and Safety of Brihat Gangadhara Churna in the Management of Irritable Bowel Syndrome: A Prospective Open-label Study. J Res Ayurvedic Sci 2019; 3 (3):92-99.

DOI: 10.5005/jras-10064-0083

License: CC BY-NC 4.0

Published Online: 00-09-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and has been confounding physicians with its multifaceted etiology and varying presentations since long. Ayurveda associates this condition with the structural or functional impairment of the organ Grahani, secondary to impairment of Agni and imbalance of Dosha in the gastrointestinal tract. Brihat Gangadhara Churna is a drug of repute preferred by physicians of Ayurveda for managing the morbidities of Agni and Vata in Koshtha. Objectives: To evaluate the clinical safety and efficacy of Brihat Gangadhara Churna in the management of IBS. Materials and methods: A prospective open-label interventional single-arm study was carried out in peripheral Institute of Central Council for Research in Ayurvedic Sciences (CCRAS). A total of 90 subjects fulfilling the inclusion and exclusion criteria were recruited in the trial, of which 85 subjects completed the trial. Brihat Gangadhara Churna, in the dose of 3 g twice a day orally after food with honey as Anupana for 12 weeks was given as intervention. Follow-up was done for a period of another 2 weeks without any medication. Assessment parameters including IBS severity score, World Health Organization-Quality of Life Brief Version of the Instrument (WHO-QOL BREF) along with Ayurvedic assessment parameters were assessed every 14 days during 12 weeks of intervention as well as at the end of follow-up period, i.e., 14th week. Paired sample t test was used to compare mean change in the parameters from baseline to 84th day. A value of <0.05 was considered significant. Results: At the end of treatment period of 84 days as compared with baseline data, significant (p < 0.001) improvement in IBS severity score and all the four domains of WHO-QOL BREF was observed. Conclusion: Brihat Gangadhara Churna in the above-mentioned dose was found effective and absolutely safe in the management of IBS.


PDF Share
  1. Foxx-Orenstein A. IBS-review and what's new. Med Gen Med 2006;8(3):20.
  2. Karantanos T, Markoutsaki T, Gazouli M, et al. Current insights into the pathophysiology of irritable bowel syndrome. Gut Pathog 2010;2(1):3. DOI: 10.1186/1757-4749-2-3.
  3. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22(10):935–942. DOI: 10.1111/j.1365-2036.2005.02671.x.
  4. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanism and practical management. Gut 2007;56(12):1770–1798. DOI: 10.1136/gut.2007.119446.
  5. Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol 2008;27(1):22–28.
  6. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977;196(4286):129–136. DOI: 10.1126/science.847460.
  7. Drossman DA. Gastrointestinal illness and the biopsychosocial model. J Clin Gastroenterol 1996;22(4):252–254. DOI: 10.1097/00004836-199606000-00002.
  8. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480–1491. DOI: 10.1053/j.gastro.2018.02.014.
  9. Nath R, Mahajon B, Sengupta A, et al. A review on clinical examination of Agnibala (digestive power). Int J Ayur Pharma Res 2014;2(2):79–82.
  10. Sharma PV, editor and translator. Charaka Samhita of Agnivesh, Chikitsa Sthana. vol. 2, Ch. 15, Ver. 52, 5th ed., Varanasi: Chaukhambha Orientalia; 2003. p. 254.
  11. Nath R, Mahajon B, Mandal SK, et al. Efficacy of Pippalī (Fruit of Piper longum Linn.) in Grahaṇīroga: a prospective open label clinical trial. J Ayur Med Sci 2017;2(2):197–203.
  12. Pandit Parasurama Sastri, Vidyasagar, editor. Sharangadhara Samhita of Sharangadhara, Madhyamakhanda, Ch. 6. Varanasi: Chaukhambha Orientalia; 2008. pp. 49–51.
  13. Bahrami HR, Hamedi S, Salari R, et al. Herbal medicines for the management of irritable bowel syndrome: a systematic review. Electron Physician 2016;8(8):2719–2725. DOI: 10.19082/2719.
  14. Weaver KR, Melkus GD, Henderson WA. Irritable bowel syndrome. Am J Nurs 2017;117(6):48–55. DOI: 10.1056/NEJMra1607547.
  15. Tiwari R, Pandya DH, Baghel MS. Clinical evaluation of Bilvadileha in the management of irritable bowel syndrome. Ayu 2013;34(4): 368–372. DOI: 10.4103/0974-8520.127717.
  16. Nath R, Mahajon B, Sengupta A, et al. Manifestation of signs and symptoms in Agnidusti. Int J Res Ayur Pharm 2016;7(Suppl 2): 150–153.
  17. Vaidya Yadavaji Trikamji Acharya, editor. Charak Samhita of Agnivesha, Siddhi Sthana, Ch. 1, Ver. 11–13, reprint ed. Varanasi: Chaukhambha Surbharati Prakashan; 2009. pp. 678–679.
  18. Qingping J, William Pelletier S. Two new diterpenoid alkaloids from Aconitum palmatum. J Nat Prod 1991;54(2):525–531.
  19. Shyaula SL. Phytochemicals, traditional uses and processing of aconitum species in Nepal. Nepal J Sci Technol 2012;12(2011):171–178. DOI: 10.3126/njst.v12i0.6496.
  20. Aslam MS, Ahmad MS. Analgesic and antiinflammatory activity of genus Aconitum: A phytochemical and ethnopharmacological review. Recent Adv Biol Med 2016;2:94–112.
  21. Kadota Y. Systematic studies of Asian Aconitum (Ranunculaceae) XIII. Species of Bhutan including a new Scandent species. J Jpn Bot 2010;85:8–24.
PDF Share